Guidelines for management of recurrent pituitary tumours recommend new drug as first line treatment

January 11, 2018, European Society of Endocrinology

New guidelines for managing recurrent pituitary tumours identify the drug temozolomide, as first line chemotherapy treatment. The guidelines, published in the European Journal of Endocrinology and produced by the European Society of Endocrinology (ESE), include a series of recommendations aimed at improving survival rates and quality of life for patients, through early identification of tumours and more effective treatment strategies.

The , located in the base of the skull, produces hormones that control many bodily processes, including metabolism, growth and reproduction. Pituitary tumours occur in approximately 1/1000 of the worldwide population and are rarely fatal. Approximately 10 to 15 percent of pituitary tumours can be considered aggressive, as they are resistant to conventional treatment or are prone to recurrence after treatment. This can cause harmful effects, including headaches, peripheral vision loss, hearing loss, and motor impairment. In some rare cases, pituitary tumours can become cancerous, leading to most patients dying within a year after the starts spreading to other parts of the body. Originally used to treat a type of fast-growing brain cancer, has recently been suggested as a potential treatment for aggressive and malignant pituitary tumours; however its effectiveness had not been thoroughly assessed.

The new guidelines are based on a systematic review of the existing literature on aggressive pituitary tumours, which found that temozolomide treatment was effective in stopping or slowing tumour growth. Following this finding, the guidelines recommend this drug as first line chemotherapy treatment after failure of conventional methods, such as radiation therapy or surgery. The guidelines also recommend that patients should be managed by a multidisciplinary team of experts, and suggest new diagnostic criteria to enable early identification of aggressive tumours.

"The rarity of the condition, the absence of controlled trials and the limited data from the literature underlined the need for clinical guidance", states Professor Gerald Raverot, from the Cancer Research Centre of Lyon and the University of Lyon, and chair of the guideline working group. Professor Raverot adds, "Although further clinical trials are needed to confirm the beneficial effects of temozolomide, these new recommendations should enable doctors to better assess the risks to patients and to identify the best for individual ."

Professor Raverot says, "Researchers and clinicians should combine efforts to establish an international register for aggressive pituitary tumours, to assess how they are diagnosed, study their progression and investigate new therapeutic options."

Explore further: Scientists exploit leaks in blood brain barrier to treat glioblastoma

More information: Gerald Raverot et al. European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas, European Journal of Endocrinology (2017). DOI: 10.1530/EJE-17-0796

Related Stories

Scientists exploit leaks in blood brain barrier to treat glioblastoma

November 6, 2017
An ovarian cancer drug can leak through the blood brain barrier to reach brain tumours and could be an effective treatment for glioblastoma, suggest results presented at the National Cancer Research Institute's (NCRI) Cancer ...

What pituitary tumours may tell us about the biology of other cancers

July 30, 2012
(Medical Xpress) -- Expression levels of a DNA repair gene called MGMT have been widely studied across many cancers as a biomarker of response to temozolomide, a chemotherapeutic agent. Now Australian scientists have published ...

New weakness found in most common childhood malignant brain tumor

December 5, 2017
A new weakness found in medulloblastoma, the most common form of childhood brain tumour, could lead to more personalised medicine and improved treatment for some patients, according to an early study by Queen Mary University ...

New guidelines aim treat brain tumors more effectively

August 10, 2017
A University of Portsmouth academic has helped to develop European guidelines to treat brain tumours more effectively.

Study in early stage breast cancer shows that even small tumors can be aggressive

September 3, 2017
Even small tumours can be aggressive, according to a study in patients with early stage breast cancer that will be presented at the ESMO 2017 Congress in Madrid. (1) Researchers found that nearly one in four small tumours ...

Revamped drug may overcome resistance in brain tumours

January 14, 2015
Cancer Research UK scientists have taken steps to overcome drug resistance in glioblastoma, the most common type of brain tumour in adults, according to research published in Molecular Cancer Therapeutics.

Recommended for you

New breath and urine tests detect early breast cancer more accurately

April 25, 2018
A new method for early and accurate breast cancer screening has been developed by researchers at Ben-Gurion University of the Negev and Soroka University Medical Center, using commercially available technology.

Do prostate cancer cells have an Achilles' heel?

April 25, 2018
Researchers at the University of Illinois at Chicago describe new ways to selectively kill prostate cancer cells by exploiting the cells' revved-up metabolism. They report their findings in the online journal, eLife.

Research shows possible new target for immunotherapy for solid tumors

April 24, 2018
Research from the University of Cincinnati (UC) reveals a potential new target to help T cells (white blood cells) infiltrate certain solid tumors.

Changes in breast tissue increase cancer risk for older women

April 24, 2018
Researchers in Norway, Switzerland, and the United States have identified age-related differences in breast tissue that contribute to older women's increased risk of developing breast cancer. The findings, published April ...

Targeting molecules called miR-200s and ADAR2 could prevent tumor metastasis in patients with colorectal cancer

April 24, 2018
Colorectal cancer is the third most common cancer worldwide and the third-leading cause of cancer-related deaths. The main cause of death in patients with colorectal cancer is liver metastasis, with nearly 70% of patients ...

Experimental arthritis drug prevents stem cell transplant complication

April 24, 2018
An investigational drug in clinical trials for rheumatoid arthritis prevents a common, life-threatening side effect of stem cell transplants, new research from Washington University School of Medicine in St. Louis shows. ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.